Rosuvastatin: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 22: | Line 22: | ||
! Lovastatin (Mevacor) | ! Lovastatin (Mevacor) | ||
! Simvastatin (Zocor) | ! Simvastatin (Zocor) | ||
! Rosuvastatin (Crestor) | ! [[Rosuvastatin]] (Crestor) | ||
|- | |- | ||
! T<sub>max</sub> (hr) | ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ||
! 2.5 | ! 2.5 | ||
! 1 | ! 1 | ||
| Line 31: | Line 31: | ||
! 4 | ! 4 | ||
|- | |- | ||
! C<sub>max</sub> (ng/ml) | ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ||
! 27-66 | ! 27-66 | ||
! 448 | ! 448 | ||
| Line 38: | Line 38: | ||
!4.34 | !4.34 | ||
|- | |- | ||
! Bioavailability (%) | ! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ||
! 12 | ! 12 | ||
! 19-29 | ! 19-29 | ||
| Line 45: | Line 45: | ||
! 20 | ! 20 | ||
|- | |- | ||
! Protein Binding (%) | ! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ||
! 80-90 | ! 80-90 | ||
! 99 | ! 99 | ||
| Line 52: | Line 52: | ||
! 88 | ! 88 | ||
|- | |- | ||
! T<sub>1/2</sub> (hr) | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
! 15-30 | ! 15-30 | ||
! 2 | ! 2 | ||
| Line 59: | Line 59: | ||
! 19 | ! 19 | ||
|- | |- | ||
! AUC (ng/ml/hr) | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
! 104 | ! 104 | ||
! | ! | ||
| Line 66: | Line 66: | ||
! 48 | ! 48 | ||
|- | |- | ||
! IC<sub>50</sub> (nM) | ! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ||
! 154 | ! 154 | ||
! 198 | ! 198 | ||